These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 4859014

  • 61. [An open study of a new formulation of the levodopa and benserazide combination in the treatment of fluctuations of motor performance in patients with Parkinson's disease].
    Pezzoli G, Tesei S, Cossutta E, Ferrante C, Zecchinelli A, Scarlato G.
    Clin Ter; 1988 Apr 30; 125(2):115-20. PubMed ID: 2973932
    [No Abstract] [Full Text] [Related]

  • 62. Therapeutic uses and side effects of L-dopa.
    Boshes B.
    Adv Intern Med; 1972 Apr 30; 18():219-49. PubMed ID: 4576081
    [No Abstract] [Full Text] [Related]

  • 63. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J.
    Med Ann Dist Columbia; 1974 Dec 30; 43(12):587-91. PubMed ID: 4532167
    [No Abstract] [Full Text] [Related]

  • 64. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ.
    N Y State J Med; 1974 Jan 30; 74(1):47-51. PubMed ID: 4591989
    [No Abstract] [Full Text] [Related]

  • 65. Dopa-decarboxylase inhibitors.
    Lancet; 1973 May 05; 1(7810):979-80. PubMed ID: 4121597
    [No Abstract] [Full Text] [Related]

  • 66. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Zumstein H, Siegfried J.
    Eur Neurol; 1976 May 05; 14(5):321-8. PubMed ID: 949985
    [Abstract] [Full Text] [Related]

  • 67. Treatment of Parkinsonism with a combination of levodopa and the decarboxylase inhibitor and RO 46-4602 (a comparison with levodopa treatment alone).
    Dupont E, Hansen E, Melsens S, Parkenberg H, Holm P.
    Acta Neurol Scand Suppl; 1972 May 05; 51():115-7. PubMed ID: 4514334
    [No Abstract] [Full Text] [Related]

  • 68. [L-DOPA treatment of parkinsonism: analysis of the clinical course in follow-up cases].
    Ando K, Kono K, Sofue I.
    Nihon Rinsho; 1973 Oct 05; 31(10):2980-6. PubMed ID: 4798116
    [No Abstract] [Full Text] [Related]

  • 69. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL, Ringel SP, Shenker DM.
    J Neurol Neurosurg Psychiatry; 1971 Dec 05; 34(6):682-6. PubMed ID: 5158783
    [Abstract] [Full Text] [Related]

  • 70. Ro 4-4602 and levodopa in the treatment of Parkinsonism.
    Miller EM, Wiener L.
    Neurology; 1974 May 05; 24(5):482-6. PubMed ID: 4857107
    [No Abstract] [Full Text] [Related]

  • 71. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W, Danielcyk W, Neumayer E, Riederer P.
    J Neural Transm; 1973 May 05; 34(2):133-43. PubMed ID: 4722571
    [No Abstract] [Full Text] [Related]

  • 72. [Advances in the treatment of parkinsonism].
    Dowzenko A.
    Neurol Neurochir Pol; 1972 May 05; 6(2):275-80. PubMed ID: 4555308
    [No Abstract] [Full Text] [Related]

  • 73. Treatment of severe parkinsonism with L-dopa.
    Reef HE, Joffe R, Milletz H.
    S Afr Med J; 1971 May 08; 45(18):504-7. PubMed ID: 4941208
    [No Abstract] [Full Text] [Related]

  • 74. Long-term treatment of Parkinsonism with L-dopa.
    Presthus J, Holmsen R.
    Acta Neurol Scand Suppl; 1972 May 08; 51():131-2. PubMed ID: 4514340
    [No Abstract] [Full Text] [Related]

  • 75. Levodopa and pressor amine sensitivity in parkinsonism.
    Reid JL, Calne DB, George CF, Vakil SD.
    Clin Pharmacol Ther; 1972 May 08; 13(3):400-6. PubMed ID: 5026378
    [No Abstract] [Full Text] [Related]

  • 76. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P.
    Acta Neurol Scand Suppl; 1972 May 08; 51():111-3. PubMed ID: 4514333
    [No Abstract] [Full Text] [Related]

  • 77. Improved control of brittle Parkinsonism by separate administration of levodopa and benserazide.
    McLellan DL, Dean BC.
    Br Med J (Clin Res Ed); 1982 Apr 03; 284(6321):1001-2. PubMed ID: 6802383
    [Abstract] [Full Text] [Related]

  • 78. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.
    Marsden CD, Parkes JD, Rees JE.
    Lancet; 1973 Dec 29; 2(7844):1459-62. PubMed ID: 4129310
    [No Abstract] [Full Text] [Related]

  • 79. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H, Ullberg S.
    Arch Int Pharmacodyn Ther; 1972 Oct 29; 199(2):376-88. PubMed ID: 4627124
    [No Abstract] [Full Text] [Related]

  • 80. L-dopa in the treatment of Parkinsonism; a preliminary appraisal.
    Stellar S, Mandell S, Waltz JM, Cooper IS.
    J Neurosurg; 1970 Mar 29; 32(3):275-80. PubMed ID: 5416909
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.